AN2 Therapeutics Inc (ANTX)
2.265
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
2.265
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Free Cash Flow: -59.28M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -59.28M |
| December 31, 2023 | -53.29M |
| September 30, 2023 | -43.86M |
| June 30, 2023 | -41.54M |
| March 31, 2023 | -38.32M |
| Date | Value |
|---|---|
| December 31, 2022 | -33.46M |
| September 30, 2022 | -34.82M |
| June 30, 2022 | -30.02M |
| March 31, 2022 | -25.68M |
| December 31, 2021 | -20.48M |
Free Cash Flow Range, Past 5 Years
-59.28M
Minimum
Mar 2024
-20.48M
Maximum
Dec 2021
-38.08M
Average
-36.57M
Median
Free Cash Flow Benchmarks
| Revance Therapeutics Inc | -224.20M |
| Viking Therapeutics Inc | -54.87M |
| VYNE Therapeutics Inc | -27.84M |
| Aquestive Therapeutics Inc | -26.60M |
| Humacyte Inc | -83.53M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -17.59M |
| Cash from Investing (Quarterly) | 26.29M |
| Cash from Financing (Quarterly) | 0.349M |
| Free Cash Flow Per Share (Quarterly) | -0.5911 |
| Free Cash Flow Yield | -99.77% |